

慶應医学会例会

下記により例会を開催いたしますので、多数ご来聴ください。

記

日時 2019年7月8日(月) 18:30

場所 リサーチパーク1階 ラウンジ

演題 **Rapidly evolving strategies for the treatment of liver cancer**

Dan G Duda D.M.D., Ph.D.

Massachusetts General Hospital Research Institute, Harvard Medical School

Surgical treatment is a potentially curative treatment option for GI cancers such as hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). However, many of the patients treated with surgery experience disease progression. Moreover, many patients present with unresectable disease at diagnosis. In such cases, until recently, available treatment options have been very limited in efficacy, which led to dismal survival rates. More recent developments in oncology have offered renewed hope for advanced liver cancer patients. Hypofractionated radiation has shown feasibility and promise in unresectable HCC setting, and is now being tested in a randomized phase III trial (clinicaltrials.gov identifier NCT03186898). Antiangiogenic agents have strongly impacted the management of advanced HCC, with multiple drug options in first line setting (sorafenib, lenvatinib) and second line setting (regorafenib, cabozantinib, ramucirumab). Notably, immunotherapy with anti-PD-1/PD-L1 antibodies has shown potential to transform advanced HCC therapy, both in first line and second line settings, but so far they have not increased overall survival. Finally, combinations of these new strategies are very attractive approaches, as they promise durable and profound responses in advanced HCC. In order to fulfill this promise, these concepts require greater understanding based on mechanistic preclinical studies and validation in correlative studies in clinical trials as a basis to establish optimal combinatorial strategies. I will present results from clinical correlative studies and preclinical models of these diseases performed at our institution. This “bench-to-the-bedside and back” approach raise the hope for a more efficient development of targeted agents in advanced setting.

担当 外科学 教室

責任者：北川雄光 教授

担当者：茂田浩平 先生

(内線 62234)

以上

主催 慶應医学会

共催 慶應医師会

The Keio Journal of Medicine